SB 209670

SB 209670 is a potent, rationally designed, nonpeptide antagonist of endothelin receptors, specifically both endothelin-A (ETA) and endothelin-B (ETB) receptors. It inhibits the binding and activity of endothelin-1, a potent vasoconstrictor peptide implicated in the pathogenesis of hypertension and vascular injury. SB 209670 demonstrates subnanomolar potency, acting as a non-selective ETA/ETB receptor antagonist, leading to inhibition of endothelin-1–mediated vasoconstriction, resulting in antihypertensive effects in animal models. It has also shown efficacy in protecting against ischemia-induced neuronal damage and in reducing neointima formation in vascular injury models. The drug was developed and characterized by SmithKline Beecham Pharmaceuticals. Clinical pharmacology studies in humans showed linear pharmacokinetics, a half-life of 4–5 hours, and evidence of renal vasodilatory effects without natriuresis[4][5][7].